Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 363302 Adrenal Elixir

ARTG entry for Medicine Listed

Sponsor Greal Labs Pty Ltd

Postal Address PO Box 193, Fitzroy, VIC, 3065

Australia

ARTG Start Date 27/04/2021

Product Category Medicine

Status Active

Approval Area Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Adrenal Elixir

Product Type Single Medicine Product Effective Date 27/04/2021

Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Maintain/support energy levels

Traditionally used in Ayurvedic medicine to maintain/support healthy adrenal gland function

Traditionally used in Western herbal medicine to adaptogen/Help body adapt to stress

Enhance/promote body adaptation to stress

Decrease/reduce/relieve symptoms of stress

Decrease/reduce/relieve symptoms of mild anxiety

Enhance/improve/promote/increase cognitive performance

Maintain/support cognitive function/mental function

Support healthy emotional/mood balance

Maintain/support healthy sexual function in healthy females

Indication Requirements

Product presentation must not imply or refer to chronic fatigue syndrome.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to any adrenal related diseases.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must only refer to mild anxiety.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Contains lactose (or words to that effect).

If you are pregnant, or considering becoming pregnant, do not take without consulting a health professional' (or words to that effect).

Page 1 of 2



Australian Government

Department of Health

Therapeutic Goods Administration

Additional Product information

Dack	Ciza/	Poison	inf	arma	hian

Pack Size **Poison Schedule**

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Eleutherococcus senticosus root Extract dry concentrate	150 mg
Equivalent: Eleutherococcus senticosus (Dry)	3 g
Ocimum tenuiflorum leaf Extract dry concentrate	100 mg
Equivalent: Ocimum tenuiflorum (Dry)	1.3 g
Rhodiola rosea root Extract dry concentrate	170 mg
Equivalent: Rhodiola rosea (Dry)	1.7 g
Withania somnifera root Extract dry concentrate	300 mg
Equivalent: Withania somnifera (Dry)	3.75 g
Other Ingredients (Excipients)	

Acacia

colloidal anhydrous silica

hypromellose lactose

Oryza sativa purified water

Sunflower Oil

[©] Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.